Ignite Creation Date:
2024-05-06 @ 3:38 AM
Last Modification Date:
2024-10-26 @ 11:36 AM
Study NCT ID:
NCT02336451
Status:
COMPLETED
Last Update Posted:
2020-04-21
First Post:
2015-01-08
Brief Title:
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain andor to Leptomeninges
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-04-01
Start Date Type:
ACTUAL
Primary Completion Date:
2019-02-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-02-06
Completion Date Type:
ACTUAL
First Submit Date:
2015-01-08
First Submit QC Date:
January 12 2015
Study First Post Date:
2015-01-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2020-02-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-04-08
Last Update Post Date:
2020-04-21
Last Update Post Date Type:
ACTUAL